San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
Good news for anyone who thought Fitbit's move toward the smartwatch market would be a move away from health: The wearable maker has just announced a partnership with Dexcom that will bring data from ...
It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...
DexCom is expected to remain an outperformer in the healthcare sector in 2024, driven by M&A activity and the growth of GLP-1 weight loss drugs. The company's continuous glucose monitoring ("CGM") ...
Hosted on MSN
DexCom: Revenue Up, EPS Misses Mark
DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue, which ...
DexCom is a leading healthcare stock that has seen significant growth, with shares returning close to 1,400% in the past decade. DXCM stock has faced resistance and is currently 37% below its all-time ...
Hosted on MSN
DexCom (DXCM) Stock Is Up, What You Need To Know
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 3.7% in the afternoon session after it rebounded from a steep sell-off that was triggered by its long-term revenue growth outlook. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback